David Novak

Item: David Novak
Rating: 1.13
Author: StockAnalysis.com

Stock Analyst at Raymond James

(1.13)

# 3,735

Out of 5,064 analysts

Total ratings

44.44%

Success rate

-9.31%

Average return

Main Sectors:

Top Industries:

Stocks Rated by David Novak

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	ZYME Zymeworks	Downgrades: Outperform	$74	$24.02	+208.08%	6	Dec 10, 2021
	CBIO Crescent Biopharma	Maintains: Outperform	$300 → $270	$13.06	+1,967.38%	1	Feb 4, 2021

Zymeworks

Dec 10, 2021

Downgrades: Outperform

Price Target: $74

Current: $24.02

Upside: +208.08%

Crescent Biopharma

Feb 4, 2021

Maintains: Outperform

Price Target: $300 → $270

Current: $13.06

Upside: +1,967.38%